Intervention Review

Intravesical gemcitabine for non-muscle invasive bladder cancer

  1. Gabriel Jones2,
  2. Anne Cleves3,
  3. Timothy J Wilt4,
  4. Malcolm Mason5,
  5. Howard G Kynaston6,
  6. Mike Shelley1,*

Editorial Group: Cochrane Prostatic Diseases and Urologic Cancers Group

Published Online: 18 JAN 2012

Assessed as up-to-date: 7 JUN 2011

DOI: 10.1002/14651858.CD009294.pub2


How to Cite

Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD009294. DOI: 10.1002/14651858.CD009294.pub2.

Author Information

  1. 1

    Velindre NHS Trust, Cochrane Prostatic Diseases and Urological Cancers Unit, Research Dept, Cardiff, Wales, UK

  2. 2

    Research Department, Velindre NHS Trust, Cochrane Prostatic Diseases and Urological Cancers Unit, Cardiff, Wales, UK

  3. 3

    Cardiff University Velindre Hospital, Cancer Research Wales Library, Cardiff, Wales, UK

  4. 4

    VAMC, General Internal Medicine (111-0), Minneapolis, Minnesota, USA

  5. 5

    Velindre Hospital, Clinical Oncology, Cardiff, UK

  6. 6

    Cardiff University, Department of Surgery, Cardiff, Wales, UK

*Mike Shelley, Cochrane Prostatic Diseases and Urological Cancers Unit, Research Dept, Velindre NHS Trust, Velindre Road, Whitchurch, Cardiff, Wales, CF4 7XL, UK. mike.shelley@wales.nhs.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 18 JAN 2012

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yair Lotan, The Challenge of Bacillus Calmette-Guérin Failure in Nonmuscle Invasive Bladder Cancer—What is the Next Step in Management?, The Journal of Urology, 2013, 190, 3, 832

    CrossRef